BLAINTRATRACHEALSUSPENSION
Approved
Jul 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
INFASURF PRESERVATIVE FREE (calfactant) by Ony Biotech is surfactant activity [moa]. Approved for bronchopulmonary dysplasia. First approved in 1998.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INFASURF PRESERVATIVE FREE is a pulmonary surfactant (calfactant) administered intratracheally as a suspension to treat bronchopulmonary dysplasia in neonates. It restores surfactant activity in the lungs, reducing respiratory distress and improving oxygenation in premature infants with compromised pulmonary function.
LOE Approaching
As a 26-year-old product in LOE-approaching stage with minimal commercial data and 30% competitive pressure, INFASURF teams are likely in defensive repositioning or transition planning mode.
Mechanism of Action
Surfactant Activity
Pharmacologic Class:
Surfactant
Indications (1)
Career Relevance
INFASURF positions are becoming scarce (0 linked jobs identified), reflecting its mature LOE-approaching lifecycle in a niche neonatal indication with minimal growth trajectory. Career mobility on this product should emphasize defensive commercial strategies, market access expertise, and readiness for product transition or portfolio role changes.
Worked on INFASURF PRESERVATIVE FREE at Ony Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.